SOD1 and neoplasm: These effects agree with the effect of CIGB-552, a synthetic anti-tumor peptide developed by The Center for Genetic Engineering and Biotechnology (CIGB), which decreases SOD1 activity, reduces cellular antioxidant capacity, and promotes ROS production.